Company Overview of Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for patients in the United States. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, and skin diseases and conditions. The company also provides patient assistance programs. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1997. The company was incorporated in 1968 and is based in Ea...
One Health Plaza
East Hanover, NJ 07936-1080
Founded in 1968
Key Executives for Novartis Pharmaceuticals Corporation
President, US Country Head and President of Novartis Corporation
Chief Financial & Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2014.
Novartis Pharmaceuticals Corporation Key Developments
Novartis Pharmaceuticals Corporation Receives FDA Approval of Farydak
Feb 23 15
Novartis announced that the US Food and Drug Administration (FDA) has approved Farydak (panobinostat, previously known as LBH589) capsules in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory (IMiD) agent. Farydak has been shown to extend the progression-free survival (PFS) benefit of the standard-of-care therapy in this patient population. Farydak is approved under accelerated approval based on PFS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The FDA's accelerated approval program gives patients access to treatments for serious or life-threatening illnesses that provide meaningful therapeutic benefit over existing treatments. The FDA has approved a risk evaluation and mitigation strategy (REMS) for Farydak. The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Farydak treatment. This FDA approval is based on efficacy and safety data in a pre-specified subgroup analysis of 193 patients who had received prior treatment with both bortezomib and an IMiD during the Phase III, randomized, double-blind, placebo-controlled, multicenter global registration trial, called PANORAMA-1.
Novartis Pharmaceuticals Corporation Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM
Feb 22 15
Novartis Pharmaceuticals Corporation Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Anne Altmeyer, VP, BD & Licensing, Head Negotiation, Oncology.
Novartis Pharmaceuticals Corporation Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 10:30 AM
Feb 18 15
Novartis Pharmaceuticals Corporation Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 10:30 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Anne Altmeyer, Vice President, BD & Licensing, Oncology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|